Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
5
×
biotech
clinical trials
life sciences
national blog main
boston blog main
national top stories
new york top stories
san francisco top stories
boston top stories
indiana blog main
indiana top stories
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
aimmune therapeutics
akcea therapeutics
allergy
alnylam pharmaceuticals
alprazolam
amgen
anaphylaxis
andrew oxtoby
archive
barry greene
billy dunn
biogen
boston
boston university
boulder/denver blog main
boulder/denver top stories
cgrp inhibitors
chronic migraine
colucid pharmaceuticals
dan ollendorf
daniel edelman
detroit blog main
What
fda
friday
5
×
drug
approval
approved
decades
medicine
new
oral
patients
therapy
time
won
acute
addresses
administration
agency
ago
aimmune
allergy
alnylam
approve
atrophy
avoid
awaits
awarded
biological
causes
collectively
condition
crossed
daily
decision
developed
discovered
eli
evrysdi
fingers
food
giant
Language
unset
Current search:
friday
×
fda
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@slashgear.com
4 years ago
FDA issues strong warning to avoid all THC and ‘street’ vapes
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision